Nanologica Ab · OMXSTO:NICA
Nanologica Ab — Q3 2023 Earnings Presentation
25 slides from Nanologica Ab's earnings presentation, Oct 27, 2023
Slide 1: Interim Report Q3 2023 Nanologica AB (publ)
INTERIM REPORT Q3 2023 NANOLOGICA AB (PUBL)
Slide 2: Period in Brief
PERIOD IN BRIEF FINANCIAL SUMMARY • Net sales for the third quarter amounted to TSEK 342 (401) and for the nine-month period to TSEK 1,368 (881) • The operating loss for the quarter amounted to TSEK -10,292 (-9,610) and for the nine-month period to TSEK -34,324 (-37,599) • Loss after tax for the qua
Slide 3: CEO Comment
CEO COMMENT DELIVERY OF SILICA TO INSULIN MANUFACTURER IN ASIA We have now delivered silica against the order we received last year from one of the world's largest insulin manufacturers in Asia. This means that we are taking a big step towards establishing ourselves as a recognized supplier of high-
Slide 4: This is Nanologica
THIS IS NANOLOGICA Better and cheaper medicine through porous silica Nanologica is a Swedish nanotechnology company world-leading in developing nanoporous silica particles for purification by chromatography. A proprietary production method enables the company to create supreme products by precisely
Slide 5: Business Area Chromatography
BUSINESS AREA CHROMATOGRAPHY In October, silica was delivered to an insulin During the third quarter, the most intensive sales manufacturer in Asia against an order received work was conducted in China. In September, last year. The delivered silica is for evaluation in Nanologica participated in the
Slide 6: Business Area Drug Development
BUSINESS AREA DRUG loss after tax for the quarter amounted to TSEK -11,554 (-10,988) and for the nine-month period to DEVELOPMENT TSEK -38,318 (-40,376). The business area is currently down-prioritized in favor of Chromatography. As a result, the Earnings per share before and after dilution were bus
Slide 7: Fluctuations in Revenue Generation, Employees and Cash
equipment for large-scale production of silica at quarter amounted to TSEK -41 (-2,788) and for the contract manufacturer Sterling Pharma the nine-month period to TSEK -13,972 (-44,963). Solutions. The book value of tangible fixed assets The investments during the quarter are related to amounted to
Slide 8: Partnerships, Collaborations and Essential Agreements; The Share
PARTNERSHIPS, share in the company at a subscription price equivalent to SEK 30 during the period 1 August COLLABORATIONS AND 2026 to 30 November 2026. Based on the existing ESSENTIAL AGREEMENTS number of shares, the dilution will be a maximum No new partnerships, collaborations or essential of 0.7
Slide 9: Risks and Uncertainties, External Factors, Auditors Review
RISKS AND UNCERTAINTIES affected by a higher interest rate situation during The company makes assumptions, assessments the term of the loans. Regarding fluctuations in and estimates that affect the content of the exchange rates, the company has manufacturing financial statements. Actual outcomes may
Slide 10: Financial Reports and Notes
Si NZ GICA FINANCIAL REPORTS AND NOTES
Slide 11: Consolidated Income Statement
CONSOLIDATED INCOME STATEMENT Nanologica’s Interim Report Q3 2023 11
Slide 12: Consolidated Balance Sheet
CONSOLIDATED BALANCE SHEET Nanologica’s Interim Report Q3 2023 12
Slide 13: Consolidated Statement of Changes in Equity and Cash Flow Statement
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY CONSOLIDATED CASH FLOW STATEMENT Nanologica’s Interim Report Q3 2023 13
Slide 14: Notes
NOTES NOTE 1 GENERAL INFORMATION This report covers the Swedish parent company Nanologica AB (publ), corporate registration number 556664-5023, and its subsidiaries. The parent company is a limited liability company with its registered office in Stockholm, Sweden. The address of the main office is F
Slide 15: Segment Information
Segment information is provided only for the group. In the table below, the business area Chromatography is titled Chroma, and the business area Drug Development is titled DD. Nanologica’s Interim Report Q3 2023 15
Slide 16: Note 5 Distribution of Income; Note 6 Financial Assets at Fair Value
NOTE 5 DISTRIBUTION OF INCOME Nanologica's distribution of revenues for sales of goods and provision of services at a specific time and over time divided per geographic market and reported separately for major customers. All revenue is at a specific time. NOTE 6 FINANCIAL ASSETS AT FAIR VALUE Fair v
Slide 17: Note 7 Inventories; Note 8 Related Party Transactions
Short-term financial investments Holdings in short-term financial investments are continuously measured at fair value with a change in value in profit or loss. Holdings in listed shares are continuously valued at fair value according to Level 1 of the valuation hierarchy. Listed holdings are valued
Slide 18: Note 9 Significant Events After the Period; Note 10 Definitions
Transactions during the third quarter • Costs regarding loans from Flerie Invest AB amounted to TSEK 1,411 during the quarter and relate to interest and commitment fee. Payments regarding loans amounted to TSEK 1,340 during the quarter. • Sales of analytical columns to Nanghavi Chromatography Soluti
Slide 19: Derivation of Alternative Performance Measures
* Derivation of alternative performance measures * When the operating profit/loss is negative, no recalculation regarding dilution is made. Nanologica’s Interim Report Q3 2023 19
Slide 20: Group Quarterly Data
GROUP QUARTERLY DATA * Alternative performance measures that are not defined by IFRS. For definition, please see note 10. Nanologica’s Interim Report Q3 2023 20
Slide 21: Income Statement for the Parent Company
INCOME STATEMENT FOR THE PARENT COMPANY STATEMENT OF COMREHENSIVE INCOME FOR THE PARENT COMPANY Nanologica’s Interim Report Q3 2023 21
Slide 22: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY Nanologica’s Interim Report Q3 2023 22
Slide 23: Balance Sheet for the Parent Company
BALANCE SHEET FOR THE PARENT COMPANY Nanologica’s Interim Report Q3 2023 23
Slide 24: Parent Company Changes in Equity and Cash Flow Statement
STATEMENT OF CHANGES IN EQUITY FOR THE PARENT COMPANY CASH FLOW STATEMENT FOR THE PARENT COMPANY Nanologica’s Interim Report Q3 2023 24
Slide 25: Nanologica AB (publ) contact details
Nanologica AB (publ) Forskargatan 20 G SE-151 36 Södertälje Sweden Ph: +46-8-410 749 49 www.nanologica.com